2023 World Conference on Lung Cancer (Posters)-P2.17. Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis

P2.17. Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis - PDF(Abstract)

Back to course

Pdf Summary

The preliminary analysis of the Jazz EMERGE 402 trial, presented at the WCLC 2023 conference, focused on the real-world safety and dosing of lurbinectedin in patients with small cell lung cancer (SCLC). Lurbinectedin is a recently approved treatment for SCLC that has shown promise in clinical trials. <br /><br />The EMERGE 402 trial is a phase 4 observational study that collects data on the effectiveness, safety, and quality of life of patients with SCLC who are prescribed lurbinectedin in real-world settings. In this preliminary analysis, the authors reported on the safety and dosing results.<br /><br />Between June 2021 and February 2023, 103 patients were treated with lurbinectedin. All patients had previously received platinum-based chemotherapy, and 70% had also received immunotherapy. The median age of the patients was 67 years, and the majority were over 65 years old. A subset of patients had central nervous system involvement or an Eastern Cooperative Oncology Group performance status of 2.<br /><br />Lurbinectedin monotherapy was administered as second-line therapy for 54% of the patients and as third- or later-line therapy for 45%. Granulocyte colony-stimulating factor (G-CSF) was given to a portion of the patients for prophylaxis against neutropenia. The median number of treatment cycles was 3, with a median duration of treatment exposure of 81 days.<br /><br />Overall, the safety profile of lurbinectedin in this analysis was consistent with previous reports from clinical trials. Treatment-related adverse events were reported in 35% of patients, with no incidence of febrile neutropenia. Adverse events led to treatment discontinuation in 10% of patients, with disease progression and death being the most common reasons for discontinuation.<br /><br />The authors concluded that the EMERGE 402 trial is enrolling a broader population of SCLC patients compared to previous trials, and the real-world safety profile of lurbinectedin is generally consistent with the previous clinical trial results. The use of G-CSF likely contributed to the low rates of neutropenia seen in this analysis.<br /><br />These findings provide valuable insights into the real-world use of lurbinectedin in SCLC patients and support its continued use as a treatment option for this patient population.

Asset Subtitle

Balazs Halmos

Meta Tag

Speaker Balazs Halmos

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

Jazz EMERGE 402 trial

WCLC 2023 conference

real-world safety

dosing

lurbinectedin

small cell lung cancer

SCLC

phase 4 observational study

effectiveness

quality of life